SGHT Insider Trading

Insider Ownership Percentage: 28.90%
Insider Buying (Last 12 Months): $85,532.40
Insider Selling (Last 12 Months): $1,143,023.22

Sight Sciences Insider Trading History Chart

This chart shows the insider buying and selling history at Sight Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$81ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Sight Sciences Share Price & Price History

Current Price: $2.38
Price Change: Price Increase of +0.12 (5.31%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for SGHT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$2.38Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Sight Sciences (NASDAQ:SGHT)

55.51% of Sight Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SGHT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$19Mbought$3.81MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal InflowsTotal Outflows
Sight Sciences logo
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Read More on Sight Sciences

Today's Range

Now: $2.38
Low: $2.24
High: $2.42

50 Day Range

MA: $2.58
Low: $2.09
High: $3.07

52 Week Range

Now: $2.38
Low: $2.03
High: $8.45

Volume

76,692 shs

Average Volume

208,986 shs

Market Capitalization

$122.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.46

Who are the company insiders with the largest holdings of Sight Sciences?

Sight Sciences' top insider shareholders include:
  1. Paul Badawi (CEO)
  2. D1 Capital Partners LP (Major Shareholder)
  3. David Badawi (CTO)
  4. Staffan Encrantz (Director)
  5. Matthew Link (Insider)
  6. Alison Bauerlein (CFO)
  7. Sam Boong Park (COO)
  8. Jeremy B Hayden (Insider)
  9. Manohar K Raheja (EVP)
Learn More about top insider investors at Sight Sciences.